Edward W. Ferguson
Washington University in St. Louis
5 Papers
35 Citations
Edward W. Ferguson is an academic researcher from Washington University in St. Louis. The author has contributed to research in topics: Tissue factor pathway inhibitor & Paraplegia. The author has an hindex of 4, co-authored 5 publications.
Chat about Author
Papers
Tissue factor pathway inhibitor protects the ischemic spinal cord.
Basem Koudsi,David M. Chatman,Beth A. Ballinger,Edward W. Ferguson,Bruce A. Kraemer,Gary A. Miller,Tze-Chein Wun,Gist H. Farr,Samuel R. Money +8 more
TL;DR: The mechanism of action of TFPI is not completely understood, yet this drug may hold promise in the prevention of IR injury of the spinal cord.
27
Identifying inaccuracies on emergency medicine residency applications.
Eric D. Katz,Lee W. Shockley,Lawrence E. Kass,David S. Howes,Janis P. Tupesis,Christopher S. Weaver,Osman Sayan,Victoria Hogan,Jason Begue,Diamond Vrocher,Jackie Frazer,Timothy Evans,Gene Hern,Ralph Riviello,Antonio Rivera,Keith Kinoshita,Edward W. Ferguson +16 more
TL;DR: This is the largest study to date of accuracy on application for residency and the first such multi-centered trial, with emphasis on reporting inaccuracies and warning applicants of the project's goals.
Prevention of spinal cord injury after transient aortic clamping with tissue factor pathway inhibitor
Basem Koudsi,Chester D. Yu,Edward W. Ferguson,Gary A. Miller,Kurt D. Merkel,Tze-Chein Wun,Bruce A. Kraemer +6 more
TL;DR: Recombinant tissue factor pathway inhibitor (rTFPI) has unique inhibitory properties that make it an effective agent in limiting postoperative paraplegia associated with spinal ischemia.
9
Depression among emergency medicine residents over an academic year
TL;DR: Season, number of hours worked, rotation type, postgraduate year, PGY, and gender all failed to predict depression among EM residents in this single-center trial.